21/01/2009Siemens AG, Healthcare Sector
Siemens Healthcare received CE marking approval to sell the new VERSANT kPCR Molecular System and the VERSANT HIV-1 RNA 1.0 Assay (kPCR) for monitoring the viral load of HIV-1 infected patients who are undergoing antiviral therapy. Viral load testing measures the plasma levels of the virus, which is critical when monitoring and guiding patients’ HIV therapy. "With nearly three million people diagnosed as HIV positive each year, innovation to improve both workflow and patient care is critical,” said Donal Quinn, CEO, Siemens Healthcare Diagnostics. “We are pleased to offer clinical laboratories leading-edge molecular technology that supports effective diagnosis and treatment of this challenging and devastating infectious disease." The VERSANT kPCR Molecular System, a kinetic polymerase chain reaction analyzer, delivers excellent assay performance with high sensitivity and broad range. The system delivers versatility through its quality nucleic acid extraction technology and ability to streamline workflow and improve efficiency in the clinical laboratory. The fully automated system offers enhanced software that interfaces with medical Laboratory Information Systems, which are used to download patient work-orders and upload patient test results. “The VERSANT kPCR Molecular System represents a significant expansion of our molecular diagnostics portfolio that will allow us to offer a growing menu of infectious disease and genomic tests, as well as sample preparation solutions for our customers,” said David Okrongly, senior vice president, molecular diagnostics, Siemens Healthcare Diagnostics. The VERSANT HIV-1 1.0 Assay (kPCR) is run on the VERSANT kPCR Molecular System and allows viral load changes to be distinguished accurately, improving HIV viral load management. It also demonstrates excellent precision across the entire reporting range and equivalent detection of HIV RNA genotypes.
Siemens Healthcare received CE marking approval to sell the new VERSANT kPCR Molecular System and the VERSANT HIV-1 RNA 1.0 Assay (kPCR) for monitoring the viral load of HIV-1 infected patients who are undergoing antiviral therapy. Viral load testing measures the plasma levels of the virus, which is critical when monitoring and guiding patients’ HIV therapy. "With nearly three million people diagnosed as HIV positive each year, innovation to improve both workflow and patient care is critical,” said Donal Quinn, CEO, Siemens Healthcare Diagnostics. “We are pleased to offer clinical laboratories leading-edge molecular technology that supports effective diagnosis and treatment of this challenging and devastating infectious disease." The VERSANT kPCR Molecular System, a kinetic polymerase chain reaction analyzer, delivers excellent assay performance with high sensitivity and broad range. The system delivers versatility through its quality nucleic acid extraction technology and ability to streamline workflow and improve efficiency in the clinical laboratory. The fully automated system offers enhanced software that interfaces with medical Laboratory Information Systems, which are used to download patient work-orders and upload patient test results. “The VERSANT kPCR Molecular System represents a significant expansion of our molecular diagnostics portfolio that will allow us to offer a growing menu of infectious disease and genomic tests, as well as sample preparation solutions for our customers,” said David Okrongly, senior vice president, molecular diagnostics, Siemens Healthcare Diagnostics. The VERSANT HIV-1 1.0 Assay (kPCR) is run on the VERSANT kPCR Molecular System and allows viral load changes to be distinguished accurately, improving HIV viral load management. It also demonstrates excellent precision across the entire reporting range and equivalent detection of HIV RNA genotypes.
1 comment:
Good fill someone in on and this fill someone in on helped me alot in my college assignement. Thank you on your information.
Post a Comment